OpenAI AI Agent Swarm Behind Hugging Face Hack 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Toyota Global Sales Fall as China Demand Slumps 
Add as a preferred source on Google
SEATTLE, April 05, 2018 -- According to Coherent Market Insights, the global clostridium difficile diagnostics and treatment market was valued at US$ 1,376.0 million in 2017 and is projected to exhibit a CAGR of 8.2% over the forecast period (2017–2025).
To know the latest trends and insights prevalent in this market, click the link below: https://www.coherentmarketinsights.com/market-insight/clostridium-difficile-diagnostics-and-treatment-market-1499
Key Trends and Analysis of the Clostridium Difficile Diagnostics and Treatment Market:
Novel therapies such as monoclonal antibodies are being developed for the treatment of C.difficile. For instance, the U.S. Food & Drug Administration approved Merck & Co., Inc.’s Zinplava (Bezlotoxumab) in 2016, and company launched Zinplava in U.K., in January 2018. CutisPharma launched FIRVANQ (vancomycin hydrochloride), an oral solution, in April 2018. Increasing research and development for alternative therapies such as microbiome therapeutics and vaccines (by Pfizer, Inc., and Valneva) is expected to positively impact growth of the market over the forecast period.
Manufacturers are focusing on offering reliable and effective molecular diagnostic tests such as polymerase chain reaction based assays and point-of-care diagnostics for C.difficile. HiberGene Diagnostics received CE mark for HG C.difficile test in 2016, and DiaSorin Molecular launched clostridium difficile molecular test in 2016. GenePOC, Inc. received U.S. FDA approval for GenePOC C.difficile molecular test in the U.S. in 2017. Furthermore, bioMérieux launched Vidas C.difficile toxin A&B test, for clostridium difficile A and B toxins in 2017.
Request Sample Copy before Buying
Key Market Takeaways:
- The market is expected to exhibit CAGR of 8.2% during the forecast period (2017–2025). This growth is attributed to increasing adoption of rapid molecular diagnostic tests for C.difficile, to provide accurate results in low turnaround time.
- Alternative therapies such as vaccines and microbiome therapeutics are under development stage, which is expected to aid in market growth in the near future
- Asia Pacific market is expected to witness significant growth, owing to presence of generic players such as Cipla and Lupin that offer generic drugs for C.difficile
- Some of the players operating in the clostridium difficile diagnostics and treatment market include Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Abbott Laboratories, Trinity Biotech, Summit Therapeutics, Baxter International Inc., Sanofi S.A., Novartis AG, and AstraZeneca Plc.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
